Valuation: Petros Pharmaceuticals

Market Cap 2L 2L 2L 2L 3L 1.97Cr 3L 20.1L 8L 97.24L 8L 8L 3.37Cr P/E 2024
-0.12x
P/E 2025 -0.01x
Enterprise Value -49.29L -43.21L -39.85L -36.92L -70L -47Cr -71.21L -4.77Cr -1.86Cr -23Cr -1.85Cr -1.81Cr -80Cr EV / Sales 2024
1.49x
EV / Sales 2025 -
Free-Float
-
Yield 2024 *
-
Yield 2025 -
1 day-3.57%
1 week-7.35%
Current month-7.35%
1 month-23.79%
3 months-14.09%
6 months-37.00%
Current year-40.94%
1 week 0
Extreme 0.004
0.01
1 month 0
Extreme 0.004
0.01
Current year 0
Extreme 0.004
0.01
1 year 0
Extreme 0.0017
0.03
3 years 0
Extreme 0.0017
118.5
5 years 0
Extreme 0.0017
1,300
10 years 0
Extreme 0.0017
1,489.98
Manager TitleAgeSince
President 49 01/12/2020
Director of Finance/CFO 66 -
Director TitleAgeSince
Chairman 55 -
Director/Board Member 62 01/12/2020
Director/Board Member 67 01/12/2020
Date Insider Type Main position Quantity % Market Cap.
18/06Other

Chief Financial Officer

6,36,004 1.5010%
05/06Free

Chairperson

3,75,000 0.8850%
05/06Free

Director

18,75,000 4.4251%

Financials

2024 2025
Net sales 51.12L 44.82L 41.33L 38.29L 72.6L 49Cr 73.85L 4.95Cr 1.93Cr 24Cr 1.92Cr 1.88Cr 83Cr -
Net income -1.43Cr -1.26Cr -1.16Cr -1.07Cr -2.03Cr -135.97Cr -2.07Cr -14Cr -5.39Cr -67Cr -5.38Cr -5.26Cr -232.19Cr 19.14L 16.78L 15.47L 14.33L 27.18L 18Cr 27.64L 1.85Cr 72.07L 8.96Cr 71.84L 70.28L 31Cr
Net Debt 36.76L 32.23L 29.72L 27.54L 52.21L 35Cr 53.11L 3.56Cr 1.38Cr 17Cr 1.38Cr 1.35Cr 60Cr -51.37L -45.04L -41.53L -38.48L -72.95L -49Cr -74.21L -4.97Cr -1.93Cr -24Cr -1.93Cr -1.89Cr -83Cr
Logo Petros Pharmaceuticals
Petros Pharmaceuticals, Inc. is a pharmaceutical company focused on expanding consumer access to medication through over-the-counter (OTC) drug development programs. The Company is pursuing access to its flagship prescription erectile dysfunction (ED) therapy, Stendra, via potential OTC designation. Stendra is a Phosphodiesterase - 5 (PDE - 5) inhibitor prescription medication for the treatment of ED and is the only patent protected PDE-5 inhibitor on the market. Stendra offers the ED therapeutic landscape a valuable addition as an oral ED therapy that may be taken once daily as early as approximately 15 minutes prior to sexual engagement, with or without food, when using the 100mg or 200mg dosing, subject to certain contraindications and limitations common among PDE-5 inhibitors. It also markets its own line of medical devices intended for ED treatment through its subsidiaries, Timm Medical and PTV, including the VED systems marketed as Osbon ErecAid and PosTVac.
Employees
3
Sector
-
Date Price Change Volume
07/26/07 $0.004725 -3.57% 3,44,978
06/26/06 $0.004900 -2.00% 3,51,209
02/26/02 $0.005000 -2.15% 1,00,565
01/26/01 $0.005110 +0.20% 1,06,118
30/26/30 $0.005100 -12.07% 4,22,385

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTPI Stock